Peter Rahmer - Sep 27, 2023 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Signature
/s/ Brian Adams, as attorney-in-fact
Stock symbol
RLAY
Transactions as of
Sep 27, 2023
Transactions value $
$15,705
Form type
4
Date filed
9/29/2023, 04:32 PM
Previous filing
Jul 31, 2023
Next filing
Nov 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $17.8K +1.66K +0.52% $10.68 320K Jun 30, 2023 Direct F1, F2, F3
transaction RLAY Common Stock Sale -$2.04K -244 -0.08% $8.38 318K Sep 27, 2023 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction.
F2 In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2023.
F3 Includes 290,341 shares underlying restricted stock units ("RSUs").
F4 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of RSUs on September 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F5 Prior to the reported transaction, the amount of securities beneficially owned by the reporting person was 318,470, with 284,835 shares underlying RSUs.
F6 Includes 283,843 shares underlying RSUs.

Remarks:

Title: Chief Corporate Development Officer